



HAMRE, SCHUMANN, MUELLER & LARSON, P.C.

AN INTERNATIONAL INTELLECTUAL PROPERTY LAW FIRM

RECEIVED
CENTRAL FAX CENTER
FEB 25 2008

FAX TRANSMISSION February 25, 2008

TO: Mail Stop: AMENDMENT
Examiner: B.I. DENTZ
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

FROM: Bryan A. Wong

OUR REF: 09548.1031USWO

TELEPHONE: (612) 455.3800

Total pages, including cover letter: 7


PTO FAX NUMBER: 571.273.8300

If all pages are NOT received, please call us at 612.455.3800 or fax us at 612.455.3801.

Title of Document: AMENDMENT UNDER 37 C.F.R. §1.111 (6 pages)

Applicant: YE
Serial No.: 10/581017
App. Filed: May 30, 2006
Group Art No.: 1625

Please charge any additional fees or credit overpayment to Deposit Account No. 50-5478. Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers, if appropriate.

By: 
Name: Bryan A. Wong
Reg. No.: 50,836

I hereby certify that this paper is being transmitted by facsimile to the U.S. Patent and Trademark Office on the date shown below.

Tracy Kimmel


Signature
Date

225 SOUTH SIXTH STREET · SUITE 2650 · MINNEAPOLIS · MN 55402
TEL 612.455.3800 · FAX 612.455.3801
WWW.HSML.COM · MAIL@HSML.COM

RECEIVED
CENTRAL FAX CENTER

FEB 25 2008

S/N 10/581017

PATENTIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	YE	Examiner:	B.I. DENTZ
Serial No.:	10/581017	Group Art Unit:	1625
Filed:	May 30, 2006	Docket No.:	09548.1031USWO
Title:	HUVASTATIN AND ITS PREPARATION AND FORMULATION COMPRISING THE HUVASTATIN		

CERTIFICATE UNDER 37 C.F.R. § 1.600

I hereby certify that this paper is being transmitted by facsimile to the U.S. Patent and Trademark Office on February 25, 2008.

By: 

Name: Tracy Kimmel

Mail Stop: AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

AMENDMENT UNDER 37 C.F.R. §1.111

Dear Commissioner:

In response to the Office Action mailed November 23, 2007, with the three month due date for response being February 23, 2008 (falling on a Saturday), please amend the above-identified application as indicated herein.

Amendments to the Claims begin on page 2 of this paper and a Listing of Claims is provided.

Remarks begin on page 4 of this paper.